HBV
Conditions
Interventions
Part A:Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
Part B:Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male or female subjects aged 18-50 years (including 18 and 50 years old); 2. Body mass index (BMI) = body weight (kg) / height 2 (M2), with body mass index (BMI) in the range of 18-28 kg / m2 (including the critical value); 3. Subjects (including partners) voluntarily took effective contraceptive measures within 6 months from screening to the last administration of the trial drug.
Exclusion criteria
Exclusion criteria: 1. Patients with abnormal clinical laboratory examination or the following diseases (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular diseases) with clinical significance within 12 months before screening; 2. Subjects of allergic constitution (allergy to various drugs and foods); 3. Patients with alcohol history; 4. Subjects who have taken any prescription drug, over-the-counter drug, any vitamin product or Chinese herbal medicine within 14 days before screening; 5. Subjects who have taken any drugs to change the activity of liver drug enzymes within 30 days before screening, such as barbiturates and rifampicin; 6. Subjects who have taken the following inhibitors or inducers of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, Oat3 or MRP4 within 30 days before screening, such as azithromycin, pantoprazole or St. John's wort; 7. Female subjects were in lactation or blood pregnancy during screening period, and the results were positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax;AUC;AE; | — |
Countries
China
Contacts
Public ContactLin Luo
Sunshine Lake Pharma Co.Ltd
Outcome results
None listed